Introduction {#Sec1}
============

Trigeminal neuralgia (TN), also known as tic doloreaux, is a debilitating pain condition characterized by agonizing, paroxysmal, and lancinating pain \[[@CR1]\]. First-line treatment includes anticonvulsant and antidepressant, but this often fails to provide pain relief and is associated with various side effects, leading patients to seek other treatments options \[[@CR1]\]. Second-line treatment modalities are given to patients whose symptoms are intractable or who cannot tolerate medication. These include surgical procedures such as microvascular decompression, and ablative procedures such as percutaneous balloon microcompression, radiofrequency rhizotomy, glycerol rhizolysis, and Gamma Knife radiosurgery (GKRS). The short-term outcomes of patients treated with GKRS are well described \[[@CR2]\]. Initial publications with the GKRS system at short median follow-up of approximately 2 years report pain relief outcomes in 70--90 % of their patients and pain-free status in 20--60 % \[[@CR3]--[@CR7]\]. As longer series with median follow-up of 19--75 months started to emerge, pain relief rates ranging from 65 to 85 % were reported \[[@CR5], [@CR8]--[@CR10]\]. However, failure to exclude patients with short-term follow-up in long-term analysis muddied the interpretation and prevented a clear understanding of longevity of GKRS\'s effectiveness in controlling TN pain. More recently, a few studies have examined long-term follow-up of GKRS in controlling pain with variable outcomes \[[@CR11]--[@CR15]\]. Here, we present our long-term institutional outcomes of GK in the treatment of TN by restricting our analysis to include only those with a minimum follow-up of 36 and after only a single GK treatment.

Methods {#Sec2}
=======

Patient characteristics {#Sec3}
-----------------------

After institutional review board approval, patient demographic characteristics, clinical presentation, treatment history, and the radiosurgical modality were retrospectively reviewed.

Patients were also followed up by a telephone questionnaire that was conducted by a medical resident and a medical student who were not involved in treatment. Patients were questioned about the time to the onset of pain relief, the degree of pain relief, and treatment complications. Based on the Barrow Neurological Institute (BNI) score for TN, we classified pain relief after treatment into five grades. A BNI I score corresponded to complete pain relief without medications; BNI II score, some pain but not requiring medications; BNI III score, some pain but adequately controlled with medications; BNI IV score, some pain not adequately controlled with medication; and BNI V score, severe pain or no pain relief. The BNI facial numbness score was used to assess complications. A BNI I score corresponded to no facial numbness; BNI II score, mild facial numbness, not bothersome; BNI III, facial numbness somewhat bothersome; and BNI IV score, facial numbness, very bothersome.

Between September 2002 and June 2010, 81 patients with TN underwent GKRS at our clinic. Indications for GKRS included medically intractable pain refractory to standard medications, refusal of invasive procedures, or failure of previous invasive procedures. Among them, we retrospectively reviewed the medical records of patients with TN undergoing GKRS treatment that had a minimum follow-up of 36 months. Ten patients had died prior to their 36 months follow-up. Fourteen patients were lost to follow-up and were lost to follow-up and on whom we were unable to obtain accurate contact information. Five patients had received GKRS treatment twice and were excluded. Two patients had bilateral disease and were excluded. Eleven patients refused to participate in the survey and adequate follow-up could not be obtained on the remaining 20 patients despite valid phone numbers and multiple attempts. Three patients were retreated but results of GKS retreatment were not included in this analysis. Rather, our report presents the results of single GKS treatment for patients with TN when using a standard treatment algorithm. A total of 36 patients were included in the final analysis with a mean follow-up of 69 months (range 36--246 months). A summary of patient characteristics is provided in Table [1](#Tab1){ref-type="table"}. None of the patients included in the final analysis had multiple sclerosis.Table 1Clinical demographic characteristics in 36 patients with medically intractable trigeminal neuralgia treated with Gamma Knife radiosurgery (GKRS)CharacteristicValueGender Male14 (39 %) Female22 (61 %)Mean age (range)71 (29--97)Prior surgery4 (11 %)Median duration in years (range)6 (0.25--30)Pain distribution V217 (47 %) V311 (30.5 %) V2,36 (17 %) V1,2,32 (5.5 %)Side of pain Right15 (42 %) Left21 (58 %)

Radiosurgery technique {#Sec4}
----------------------

All patients were treated on the 201-source 60Co Gamma Knife unit, model 4C, manufactured by Elekta instruments (Elekta, Norcross, Georgia). Treatment planning was performed jointly by a radiation oncologist, neurosurgeon, and medical physicist for all cases. After induction of local anesthesia, the Leksell Model G stereotactic coordinate frame was affixed to the head of each patient, and contrast enhanced MR imaging was performed to visualize and target the trigeminal nerve root entry zone. As a planning tool, the Leksell Gamma Plan System (Elekta) was used. A single 4-mm isocenter was placed adjacent to the trigeminal nerve root entry zone. The median peripheral dose was 45 Gy with a range of maximum dose between 80 and 90 Gy delivered to the involved trigeminal nerve root entry zone. A plugging pattern typically blocking 32 sources was used so that the surface of the brainstem was irradiated at no greater than the 20 % isodose line for any patient.

Statistical analysis {#Sec5}
--------------------

Treatment outcomes were assessed by patient self-reports of pain control and medication usage at last follow-up. A pain-free outcome was defined as BNI pain score I and pain relief or good outcome was regarded as maintaining a BNI pain score IIIa or better without requiring further surgery. Treatment failure was defined as pain returning to a BNI level of IV or V, or the patient undergoing an invasive surgical procedure due to uncontrolled pain. A recurrence was defined as a relapse to a previous lower level after attainment of any higher level of pain relief. Patients reported the time interval for a response and pain recurrence after GKRS. The date of treatment failure was considered to be the date at which pain relief became a BNI IV or V score.

Time to BNI class IV to V pain relapse was calculated with the Kaplan--Meier method. Log rank tests were performed to determine statistical differences between pain relapse curves. We conducted a univariate analysis of several factors hypothesized to influence or predict successful treatment, using Cox regression analysis: age, gender, side of pain, duration of symptoms, new facial numbness. A *p* value \<0.05 was accepted as statistically significant. All statistical calculations were performed using SPSS software, version 13.0 (SPSS, Inc., Chicago, IL, USA).

Results {#Sec6}
=======

Pain relief after GKRS {#Sec7}
----------------------

The mean time from GKRS to pain improvement was 1.6 months (range, 1 day--6 months). Of those patient that experienced immediate pain relief (29 or 80.6 %), the majority (27 or 75 %) described an early pain response to treatment within the first 2 months after GKRS, whereas two (5.5 %) patients reported symptoms relief after 2 months. Seven patients (19 %) reported no pain response. The median time to recurrence of any symptoms was 46 months (range, 6--116 months). Of the 29 patients that experienced pain relief, 17 (58.6 %) did not have any pain recurrence (BNI I), while the remaining 12 (41.4 %) had some return of some pain (BNI ≥2). Results of Kaplan--Meier analysis of response time after GKRS are displayed in Fig. [1](#Fig1){ref-type="fig"}. At median follow-up of 5 years, actuarial freedom from any pain recurrence (BNI ≥2) is 40 %.Fig. 1**a** Kaplan--Meier curve for time from Gamma Knife radiosurgery (GKRS) and freedom from any pain (BNI I). **b** Kaplan--Meier curve for time from Gamma Knife radiosurgery (GKRS) to Barrow Neurologic Institute (BNI) class IV to V pain relapse (i.e., freedom from severe pain)

At last follow-up, 26 (72.2 %) patients had good treatment outcome (BNI I, II, or III) and 10 patients (27.8 %) had treatment failure. The 10 patients with treatment failure included the seven patients who did not have any response to treatment. Kaplan--Meier analysis shows an actuarial rate freedom from severe pain of 63 % at mean last follow-up of 69 months (Fig. [1b](#Fig1){ref-type="fig"}). The patient responses at last follow-up, as determined using the BNI pain intensity scoring system, are listed in Table [2](#Tab2){ref-type="table"}. At last follow-up, 14 (39 %) of the patients had no pain and no medications (BNI I) with a median time of maintaining a BNI I pain score of 46 months (range, 36--77 months). A summary of pain outcomes at last follow-up is listed in Table [3](#Tab3){ref-type="table"}.Table 2Pain response (top 5 rows) and development of facial numbness post treatment (bottom 3 rows) at last follow-upNumber of patients (%)BNI pain intensity scale BNI I14 (39) BNI II3 (8) BNI III8 (22) BNI IV8 (22) BNI V3 (8)BNI facial numbness score BNI I--II32 (89) BNI III0 (0) BNI IV4 (11)Table 3Summary of actuarial rates of pain outcomes at last follow-upActuarial rate at 36 months (%)Actuarial rate at 69 months (%)Freedom from any pain (*n* = 36)6732Freedom from any pain recurrence in responders (*n* = 29)8340Freedom from severe pain or good treatment outcome (*n* = 36)7563

Treatment-related complications {#Sec8}
-------------------------------

The majority of the patients (26 or 72.2 %) did not experience any post-treatment facial numbness. Two patients (16.7 %) reported mild facial numbness that was not bothersome. Very bothersome facial numbness (BNI IV) was reported in a total of four patients (11.1 %) (Table [2](#Tab2){ref-type="table"}). However, all four patients had good pain treatment outcome with three reporting a posttreatment BNI pain intensity score of I and one patient reporting a BNI pain score of II at longest follow-up. All four had received a treatment dose of 45 Gy. There were no reports of decreased corneal sensation (dry eye syndrome).

Prognosticators {#Sec9}
---------------

Univariate analysis for previously published prognosticators of treatment failure is shown in Table [4](#Tab4){ref-type="table"}. No statistically significant correlation was found between treatment failure and age, gender, dose, laterality of pain, duration of symptoms, or development of new bothersome facial numbness. There was, however, a statistically significant difference between age and recurrence or persistence of any pain (BNI \>1) and age (*p* = 0.02). Patients older than 70 reported significantly better freedom from any pain compared with those less than 70 years of age.Table 4Summary of various prognosticators and development of treatment failure (BNI IV--V)VariableGood outcomeTreatment failure*p* valueNo of patients25 (69.4 %)11 (30.6 %)0.03Gender Male1660.87 Female95Age ≥70 years1540.34 \<70 years107Side of pain Right960.50 Left165Duration of symptoms \>18 months550.20 \<18 months164Dose 40 Gy750.52 45 Gy186New bothersome facial numbness400.41

Discussion {#Sec10}
==========

In their large series, Kondziolka et al. \[[@CR2]\] and Régis et al. \[[@CR7]\] reported that GKRS was a safe and effective alternative treatment to surgical procedures in the treatment of medically intractable TN. However, treatment outcomes and treatment-related complication rates have varied according to follow-up period, time for assessment of pain outcome, and different pain scores. In the present study, we report on pain outcome and side effects using standardized pain scores with a minimum 3-year follow-up to evaluate the long-term results of GKRS for TN.

Allowing for variability in grading systems among studies, our results are similar to previously published results \[[@CR11], [@CR16]\]. The incidence of early pain relief was high (80.5 %) in our series. Pain relief was noted an average of 1.6 months after treatment. This time frame is consistent with previously published data \[[@CR11], [@CR16]\]. At our institution, we have therefore taken a similar approach to others by discussing further treatment options in which no degree of pain relief has been achieved in 6 months.

Our series is one of few to include only longer term follow-up of patients undergoing GKS for TN. An increasing body of literature suggests that the beneficial effect of stereotactic radiation on TN diminishes with time. At minimum follow-up of 3 years, 67 % were pain free (BNI I) and 75 % had good treatment outcome. At a mean last follow-up of 69 months, 32 % were free from any pain and 63 % were free from severe pain. Our results are strikingly similar to previously reported long-term analysis of TN pain outcomes. In a small series with minimum follow-up of 3 years, Park et al. \[[@CR13]\] reported 17 % pain-free outcomes and 65 % with good pain outcome. Sheehan et al. \[[@CR9]\] presented a subgroup of 39 patients (minimum 3-year follow-up) in which 70 % reported pain relief and 34 % reported an "ideal" outcome (BNI grade I). At a minimum follow-up of 36 months and an average follow-up of 48 months, Riesenburger et al. \[[@CR11]\] reported on 53 patients with 58.5 % of patients experiencing good treatment outcome and 32.1 % of patients with pain-free outcome. In a more recently published series, Lee et al. \[[@CR15]\] reported 27.3 % BNI I and II outcomes and 68 % good outcomes when data from 40 patients with minimum of 60-months follow-up and an average follow-up of 92.2 months were analyzed. Finally, in one of the largest series, Little and associates \[[@CR12]\] reported actuarial data on 136 patients with a minimum follow-up duration of 4 years. At a mean follow-up of 6.3 years, they report 32 % of their patients being pain free off and off medication at 7 years and 83 % with good treatment outcomes, although they did include retreatment of patients \[[@CR12]\]. In our series, we had lower response rates than those of Little et al. but results of retreatment were not included, which we would have expected to have increased the rate of overall successful pain relief.

Our incidence of new-onset facial numbness at 11 % was in accordance with previously published incidences. The reported incidence of facial numbness has ranged from 6 to 37 % \[[@CR2], [@CR5], [@CR7], [@CR9], [@CR11], [@CR16]--[@CR18]\] with most series reporting new-onset numbness in \~10 % of treated patients. Similar to Riesenburger et al. \[[@CR11]\], our series did not reveal any statistically significant correlation between known prognosticators such as age, gender, side of pain, duration of pain, or new-onset facial numbness and development of treatment failure at last follow-up.

However, a statistically significant correlation was found between age and recurrence of any pain with age \>70 predicting a more favorable outcome radiosurgery. In their series examining long-term pain outcomes of TN, Han et al. \[[@CR14]\] reported a similar correlation between older age \>70 and favorable outcome in terms of pain recurrence after radiosurgery. The issue of age has been controversial in the literature as other series have reported a prognostic association between younger age and achieving and maintaining pain relief \[[@CR8], [@CR19]\]. Both of these studies, however, have been based on shorter follow-up period after radiosurgery. A correlation between history of prior ablative surgery and pain outcomes has long been established for TN pain recurrence after radiosurgery \[[@CR1]\]. Given the low number of events in our series with only four patients having had undergone previous ablative procedures, that correlation could not be tested in our current study. Whether that could have biased our data in favor of a positive correlation between older age and pain recurrence after radiosurgery remains an uncertain question that needs to be addressed in larger sample sized studies.

Finally, although the median peripheral dose of 45 Gy that our institution has adopted is higher than the currently recommended dose (40 Gy) necessary to provide pain relief while avoiding toxicity \[[@CR19], [@CR20]\], we did not find a correlation between dose and either development of treatment failure at last follow-up or development of new bothersome facial numbness. Our analysis could have been underpowered in detecting a dose--outcome correlation, especially since the rate of trigeminal nerve dysfunction has been reported to decline with the increased follow-up duration \[[@CR20]\]. Variations in other technical nuances of radiosurgery between institutions such as volume of nerve treated and anatomical location of the target (and hence the dose to the intraaxial portion of fifth nerve fibers in the brainstem) could have also confounded the impact of "high dose" (90 Gy) on both the probability of long-term pain control and fifth nerve dysfunction \[[@CR21]\].

Conclusion {#Sec11}
==========

GKRS is a safe, effective, and minimally invasive treatment modality for patients with medically intractable TN or those who are ineligible or refuse open surgery. Our results demonstrate that a single GKS treatment is associated with good outcomes in nearly 60 % of patients in an average follow-up period of approximately 6 years. While most pain recurrence develops within 6 months of treatment, treatment failure may still manifest years later. Our results also suggest that patients \>70 presenting with medically intractable TN are good candidates for radiosurgery. The small sample size and retrospective nature of our study design limit the power of our outcome observations. Additionally, although pain intensity and numbness scales are validated tools for the quantification of pain and numbness, they are subjective outcome measures because they are dependent on personal interpretations and variation. The results of this study should, however, help clinicians provide important information to patients so they can have realistic expectations and be able to weigh the risks and benefits relative to the various available treatment options.
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Prior to the phone interview, the following are telephone consent script for retrospective review of efficacy, treatment outcomes, and toxicity of Gamma Knife radiosurgery for treatment of trigeminal neuralgia. This consent was standardized every time that a patient is contacted.

After the investigator introduces himself/herself, the purpose of the phone interview is stated as research aimed at gaining more knowledge about GammaKnife treatment outcomes. The participant is then asked for willingness to participate in the phone interview. If they accept then the investigator proceeds with the survey as detailed under the Methods section of the manuscript. If they decline, then the participant is thanked for their time and the phone call is terminated.
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